Generic drugs – essential for the sustainability of healthcare systems with numerous strategies to enhance their use

Brian Godman, Amos Massele, Joseph Fadare, Hye-Young Kwon, Amanj Kurdi, Francis Kalemeera, Shazhad Hussain, Alice Pisana, Johanna C Meyer

Research output: Contribution to journalEditorialpeer-review

3 Downloads (Pure)

Abstract

The increasing use of lower-cost multiple sourced medicines (generics) and biosimilars are essential to attain or retain universal healthcare in the face of continual pressure on available resources. Alongside this, reduce patient co-payments and enhance access to medicines in countries with high co-payments where affordability was an issue. Supply-side measures, including aggressive procurement practices and increased transparency in the manufacture and pricing of generics, can appreciably lower the price of generics. Such measures alongside demand-side measures can enhance savings versus originators as well as increase access to standard medicines. However, there needs to be trust in the generics to maximise savings. The same applies to biosimilars. Multiple demand-side measures can also appreciably enhance the preferential prescribing of multiple sourced medicines versus still patented medicines in a class or related class without compromising care. As a result, enhance utilisation at lower costs. Countries can learn from each other when planning or instigating reforms, and this will grow.
Original languageEnglish
Article number126
Number of pages11
JournalPharmaceutical Sciences and Biomedical Analysis Journal
Volume4
Issue number1
Publication statusPublished - 5 Aug 2021

Keywords

  • generic drugs
  • biosimilars
  • healthcare sustainability

Fingerprint

Dive into the research topics of 'Generic drugs – essential for the sustainability of healthcare systems with numerous strategies to enhance their use'. Together they form a unique fingerprint.

Cite this